Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014 (2014), Article ID 858715, 13 pages
http://dx.doi.org/10.1155/2014/858715
Clinical Study

The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil

1Department Experimental Medicine, Sapienza University, 00161 Rome, Italy
2Endocrinology Unit, Maggiore-Bellaria Hospital, 40133 Bologna, Italy
3University of Tor Vergata, Department of System Medicine, 00133 Rome, Italy
4Centre Cryopreservation of Male Gamete, University of Padova, 35122 Padua, Italy
5Biomedicine, University of Florence, 50121 Florence, Italy
6SIAMS, Italian Society of Andrology and Sexual Medicine, Italy

Received 15 September 2013; Revised 8 December 2013; Accepted 28 December 2013; Published 15 May 2014

Academic Editor: Janaka Karalliedde

Copyright © 2014 Andrea M. Isidori et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. W. Lewis, K. S. Fugl-Meyer, G. Corona et al., “Definitions/epidemiology/risk factors for sexual dysfunction,” Journal of Sexual Medicine, vol. 7, no. 4, pp. 1598–1607, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Esposito, F. Giugliano, E. Martedì et al., “High proportions of erectile dysfunction in men with the metabolic syndrome,” Diabetes Care, vol. 28, no. 5, pp. 1201–1203, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. G. De Berardis, M. Franciosi, M. Belfiglio et al., “Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked,” Diabetes Care, vol. 25, no. 2, pp. 284–291, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Burchardt, T. Burchardt, L. Baer et al., “Hypertension is associated with severe erectile dysfunction,” Journal of Urology, vol. 164, no. 4, pp. 1188–1191, 2000. View at Google Scholar · View at Scopus
  5. T. Suetomi, K. Kawai, S. Hinotsu et al., “Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men,” Journal of Sexual Medicine, vol. 5, no. 6, pp. 1443–1450, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Corona, M. Monami, G. Rastrelli et al., “Is metabolic syndrome a useless category in subjects with high cardiovascular risk? Results from a cohort study in men with erectile dysfunction,” Journal of Sexual Medicine, vol. 8, no. 2, pp. 504–511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Aizawa, N. Kamimura, H. Watanabe et al., “Cardiovascular risk factors are really linked in the metabolic syndrome: this phenomenon suggests clustering rather than coincidence,” International Journal of Cardiology, vol. 109, no. 2, pp. 213–218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Aversa, A. M. Isidori, D. Gianfrilli et al., “Are subjects with erectile dysfunction aware of their condition? Results from a retrospective study based on an Italian free-call information service,” Journal of Endocrinological Investigation, vol. 27, no. 6, pp. 548–556, 2004. View at Google Scholar · View at Scopus
  10. T. H. Jones and F. Saad, “The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process,” Atherosclerosis, vol. 207, no. 2, pp. 318–327, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Basaria, D. C. Muller, M. A. Carducci, J. Egan, and A. S. Dobs, “Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy,” Cancer, vol. 106, no. 3, pp. 581–588, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. S. S. Franklin, S. A. Khan, N. D. Wong, M. G. Larson, and D. Levy, “Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study,” Circulation, vol. 100, no. 4, pp. 354–360, 1999. View at Google Scholar · View at Scopus
  13. M. Domanski, G. Mitchell, M. Pfeffer et al., “Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT),” Journal of the American Medical Association, vol. 287, no. 20, pp. 2677–2683, 2002. View at Google Scholar · View at Scopus
  14. C. D. A. Stehouwer, R. M. A. Henry, and I. Ferreira, “Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease,” Diabetologia, vol. 51, no. 4, pp. 527–539, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Mannucci, L. Lambertucci, M. Monami et al., “Pulse pressure and mortality in hypertensive type 2 diabetic patients. A cohort study,” Diabetes/Metabolism Research and Reviews, vol. 22, no. 3, pp. 172–175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Hajjar and T. A. Kotchen, “Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000,” Journal of the American Medical Association, vol. 290, no. 2, pp. 199–206, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Assmann, P. Cullen, T. Evers, D. Petzinna, and H. Schulte, “Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM,” European Heart Journal, vol. 26, no. 20, pp. 2120–2126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Corona, E. Mannucci, F. Lotti et al., “Pulse pressure, an index of arterial stiffness, is associated with androgen deficiency and impaired penile blood flow in men with ED,” Journal of Sexual Medicine, vol. 6, no. 1, pp. 285–293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Kienitz and M. Quinkler, “Testosterone and blood pressure regulation,” Kidney and Blood Pressure Research, vol. 31, no. 2, pp. 71–79, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Isidori, J. Buvat, G. Corona et al., “A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment—a systematic review,” European Urology, vol. 65, pp. 99–112, 2014. View at Google Scholar
  21. L. Manzoli, W. Palumbo, P. Ruotolo, M. Panella, A. Mezzetti, and F. Di Stanislao, “Cardiovascular risk of the general population assessed through SCORE and CUORE charts: an extensive survey by the general practitioners from Abruzzo, Italy,” International Journal of Cardiology, vol. 144, no. 1, pp. 47–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Palmieri, R. Rielli, L. Demattè et al., “CUORE project: implementation of the 10-year risk score,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 18, no. 4, pp. 642–649, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. E. A. Jannini, A. M. Isidori, A. Aversa, A. Lenzi, and S. E. Althof, “Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions,” The Journal of Sexual Medicine, vol. 10, pp. 2359–2369, 2013. View at Google Scholar
  24. D. F. Penson, D. M. Latini, D. P. Lubeck, K. L. Wallace, J. M. Henning, and T. F. Lue, “Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database,” Diabetes Care, vol. 26, no. 4, pp. 1093–1099, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. E. A. Jannini, A. M. Isidori, G. L. Gravina et al., “The ENDOTRIAL Study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction,” Journal of Sexual Medicine, vol. 6, no. 9, pp. 2547–2560, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. R. C. Rosen, J. C. Cappelleri, and N. Gendrano III, “The International Index of Erectile Function (IIEF): a state-of-the-science review,” International Journal of Impotence Research, vol. 14, no. 4, pp. 226–244, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Palmieri, S. Panico, D. Vanuzzo et al., “Evaluation of the global cardiovascular absolute risk: The Progetto CUORE individual score,” Annali dell'Istituto Superiore di Sanita, vol. 40, no. 4, pp. 393–399, 2004. View at Google Scholar · View at Scopus
  28. D. Gianfrilli, R. Lauretta, D. C. Di et al., “Propionyl-L-carnitine, L-arginine and niacin in sexual medicine: a nutraceutical approach to erectile dysfunction,” Andrologia, vol. 44, supplement 1, pp. 600–604, 2012. View at Google Scholar
  29. “Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report,” Circulation, vol. 106, pp. 3143–3421, 2002.
  30. A. M. Isidori, E. Giannetta, and A. Lenzi, “Male hypogonadism,” Pituitary, vol. 11, no. 2, pp. 171–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Aversa, R. Bruzziches, and G. Spera, “Diagnosing erectile dysfunction: the penile dynamic colour duplex ultrasound revisited,” International Journal of Andrology, vol. 28, supplement 2, pp. 61–63, 2005. View at Google Scholar · View at Scopus
  32. G. Mancia, M. Bombelli, G. Corrao et al., “Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis,” Hypertension, vol. 49, no. 1, pp. 40–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. I. M. Thompson, C. M. Tangen, P. J. Goodman, J. L. Probstfield, C. M. Moinpour, and C. A. Coltman, “Erectile dysfunction and subsequent cardiovascular disease,” Journal of the American Medical Association, vol. 294, no. 23, pp. 2996–3002, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Corona, M. Monami, V. Boddi et al., “Male sexuality and cardiovascular risk. A cohort study in patients with erectile dysfunction,” Journal of Sexual Medicine, vol. 7, no. 5, pp. 1918–1927, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Nehra, G. Jackson, M. Miner et al., “The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease,” Mayo Clinic Proceedings, vol. 87, pp. 766–778, 2012. View at Google Scholar
  36. R. O. Rosen, W. A. Fisher, I. Eardley, C. Niederberger, A. Nadel, and M. Sand, “The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population,” Current Medical Research and Opinion, vol. 20, no. 5, pp. 607–617, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. M. G. Kirby, G. Schnetzler, K. H. Zou, and T. Symonds, “Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study,” International Journal of Clinical Practice, vol. 65, no. 7, pp. 797–806, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Frantzen, T. G. W. Speel, L. A. Kiemeney, and E. J. H. Meuleman, “Cardiovascular risk among men seeking help for erectile dysfunction,” Annals of Epidemiology, vol. 16, no. 2, pp. 85–90, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. G. M. C. Rosano, F. Leonardo, P. Pagnotta et al., “Acute anti-ischemic effect of testosterone in men with coronary artery disease,” Circulation, vol. 99, no. 13, pp. 1666–1670, 1999. View at Google Scholar · View at Scopus
  40. F. Dockery, C. J. Bulpitt, S. Agarwal, C. Vernon, and C. Rajkumar, “Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer,” Journal of Andrology, vol. 30, no. 4, pp. 410–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Hougaku, J. L. Fleg, S. S. Najjar et al., “Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements,” American Journal of Physiology, vol. 290, no. 2, pp. E234–E242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Corona, M. Monami, V. Boddi et al., “Pulse pressure independently predicts major cardiovascular events in younger but not in older subjects with erectile dysfunction,” Journal of Sexual Medicine, vol. 8, no. 1, pp. 247–254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Aversa, D. Francomano, R. Bruzziches et al., “The application of digital pulse amplitude tonometry to the diagnostic investigation of endothelial dysfunction in men with erectile dysfunction,” Andrologia, vol. 43, no. 1, pp. 9–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Giannetta, D. Gianfrilli, F. Barbagallo, A. M. Isidori, and A. Lenzi, “Subclinical male hypogonadism,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 26, pp. 539–550, 2012. View at Google Scholar
  45. B. Labropoulos, E. Velonakis, and P. Oekonomakos, “Serum sex hormones in patients with coronary disease and their relationship to known factors causing atherosclerosis,” Cardiology, vol. 69, no. 2, pp. 98–103, 1982. View at Google Scholar · View at Scopus
  46. G. Corona, E. Mannucci, V. Ricca et al., “The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction,” International Journal of Andrology, vol. 32, no. 6, pp. 720–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Saad, A. Aversa, A. M. Isidori, L. Zafalon, M. Zitzmann, and L. Gooren, “Onset of effects of testosterone treatment and time span until maximum effects are achieved,” European Journal of Endocrinology, vol. 165, no. 5, pp. 675–685, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. G. S. Hughes, R. S. Mathur, and H. S. Margolius, “Sex steroid hormones are altered in essential hypertension,” Journal of Hypertension, vol. 7, no. 3, pp. 181–187, 1989. View at Google Scholar · View at Scopus
  49. J. Svartberg, D. von Mühlen, H. Schirmer, E. Barrett-Connor, J. Sundfjord, and R. Jorde, “Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø study,” European Journal of Endocrinology, vol. 150, no. 1, pp. 65–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. A. M. Isidori and A. Lenzi, “Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs,” Journal of Endocrinological Investigation, vol. 28, no. 3, pp. 14–22, 2005. View at Google Scholar · View at Scopus
  51. G. M. Reaven, “The metabolic syndrome: requiescat in pace,” Clinical Chemistry, vol. 51, no. 6, pp. 931–938, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. S. M. Grundy, “Point: The metabolic syndrome still lives,” Clinical Chemistry, vol. 51, no. 8, pp. 1352–1354, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Reaven, “Counterpoint: Just being alive is not good enough,” Clinical Chemistry, vol. 51, no. 8, pp. 1354–1357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Mannucci, M. Monami, and C. M. Rotella, “How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 17, no. 10, pp. 719–726, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Wormser, S. Kaptoge, E. Di Angelantonio et al., “Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies,” The Lancet, vol. 377, no. 9771, pp. 1085–1095, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Pasquali, M. Arcopinto, A. Renzullo et al., “Cardiovascular abnormalities in Klinefelter Syndrome,” International Journal of Cardiology, vol. 168, no. 2, pp. 754–759, 2013. View at Google Scholar
  57. G. Corona, G. Rastrelli, M. Monami et al., “Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study,” European Journal of Endocrinology, vol. 165, no. 5, pp. 687–701, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Nehra, “Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions,” Mayo Clinic Proceedings, vol. 84, no. 2, pp. 139–148, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. I. Goldstein, J. M. Young, J. Fischer, K. Bangerter, T. Segerson, and T. Taylor, “Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study,” Diabetes Care, vol. 26, no. 3, pp. 777–783, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Van Ahlen, K. Wahle, W. Kupper, A. Yassin, T. Reblin, and M. Neureither, “Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives,” Journal of Sexual Medicine, vol. 2, no. 6, pp. 856–864, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Miner, L. Gilderman, J. Bailen et al., “Vardenafil in men with stable statin therapy and dyslipidemia,” Journal of Sexual Medicine, vol. 5, no. 6, pp. 1455–1467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. I. Eardley, J. C. Lee, R. Shabsigh et al., “Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications,” Journal of Sexual Medicine, vol. 7, no. 1, pp. 244–255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Schneider, J. Gleißner, F. Merfort, M. Hermanns, M. Beneke, and E. Ulbrich, “Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial,” Journal of Sexual Medicine, vol. 8, no. 10, pp. 2904–2911, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. H. van Ahlen, J. Zumbé, K. Stauch, and J. U. Hanisch, “The Real-Life Safety and Efficacy of Vardenafil (REALISE) Study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions,” Journal of Sexual Medicine, vol. 7, no. 9, pp. 3161–3169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. V. Fonseca, A. Seftel, J. Denne, and P. Fredlund, “Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials,” Diabetologia, vol. 47, no. 11, pp. 1914–1923, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. M. M. Miner, A. Barnes, and S. Janning, “Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study,” Journal of Sexual Medicine, vol. 7, no. 5, pp. 1937–1947, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. E. Lopez-Gonzalez, M. T. Herdeiro, and A. Figueiras, “Determinants of under-reporting of adverse drug reactions: a systematic review,” Drug Safety, vol. 32, no. 1, pp. 19–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Giannetta, A. M. Isidori, N. Galea et al., “Chronic inhibition of cyclic GMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging,” Circulation, vol. 125, pp. 2323–2333, 2012. View at Google Scholar